Pancreatic Enzyme Replacement Market Report 2026

The pancreatic enzyme replacement market size has grown strongly in recent years. It will grow from $5.25 billion in 2025 to $5.65 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to limited availability of synthetic enzyme formulations, reliance on porcine-derived enzymes, low awareness of enzyme replacement therapy, hospital-centric treatment distribution, fragmented supply chains.

The pancreatic enzyme replacement market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing use of microbial and recombinant-derived enzymes, growth in chronic pancreatitis and cystic fibrosis patient base, expansion of home healthcare services, rise in oral and delayed-release formulations, integration of digital monitoring and dosage optimization. Major trends in the forecast period include increasing adoption of personalized enzyme therapy, integration of ai for dosage optimization, growth of oral powder and capsule formulations, rising demand for home healthcare enzyme solutions, expansion of hospital and clinic distribution channels.

The rising incidence of gastrointestinal diseases is expected to drive growth in the pancreatic enzyme replacement market going forward. Gastrointestinal diseases encompass disorders affecting the digestive tract, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder, often resulting in symptoms such as abdominal pain, bloating, diarrhea, and constipation. This increase in gastrointestinal disorders is primarily linked to poor dietary habits, including high consumption of processed foods, low fiber intake, and high-fat diets, which can disrupt gut health and contribute to conditions such as acid reflux, irritable bowel syndrome, and inflammatory bowel disease (IBD). Pancreatic enzyme replacement supports patients by improving digestion and nutrient absorption, alleviating symptoms such as malnutrition, bloating, and steatorrhea associated with pancreatic insufficiency. For instance, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that the number of individuals with inflammatory bowel disease exceeded 5,300, reflecting an increase of more than 3,000 members compared to 2022. Therefore, the rising prevalence of gastrointestinal diseases is driving the growth of the pancreatic enzyme replacement market.

Companies in this market are focusing on innovative formulations such as delayed-release capsules to improve enzyme stability and therapeutic efficacy for patients with pancreatic insufficiency. Delayed-release capsules are designed to release their contents at a targeted location in the digestive tract, ensuring enzymes reach the small intestine where they can aid digestion while bypassing the acidic environment of the stomach that could degrade them. For instance, in March 2025, Adalvo Limited, a Malta-based pharmaceutical manufacturer, launched Pancreatin Delayed-Release Capsules. These capsules are formulated to release enzymes specifically in the small intestine, improving efficacy for patients with exocrine pancreatic insufficiency (EPI) and conditions such as chronic pancreatitis, cystic fibrosis, and post-pancreatectomy digestive insufficiency.

In December 2023, Nestlé Health Science S.A., a Switzerland-based nutritional science company, acquired CDX-7108 from Codexis Inc. for $45 million. This acquisition allows Nestlé Health Science to advance the development and commercialization of CDX-7108, an investigational therapy designed to address the limitations of traditional pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency. Codexis Inc., a US-based protein engineering company, developed CDX-7108, a lipase variant aimed at enhancing the effectiveness of pancreatic enzyme replacement therapy (PERT). The deal enables Nestlé Health Science to continue clinical trials and bring this therapy to market, expanding treatment options for patients with EPI.

Major companies operating in the pancreatic enzyme replacement market are Johnson & Johnson, Abbott Laboratories, Viatris Inc., Nestlé Health Science S.A., Chiesi Farmaceutici S.p.A., Now Health Group Inc., AzurRx BioPharma Inc., Nordmark Arzneimittel GmbH & Co. KG, Alcresta Therapeutics Inc., Perseo Pharma AG, Digestive Care Inc., Anagram Therapeutics Inc., Entero Therapeutics Inc., Sun Pharmaceutical Industries Ltd, Laboratoires Mayoly Spindler, Recordati S.p.A., Synmosa Biopharma Corporation, Dr Falk Pharma GmbH, Enzymedica Inc., VIVUS Inc., Pharming Group NV, Dr Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, AstraZeneca plc, Bausch Health Companies Inc.

North America was the largest region in the pancreatic enzyme replacement market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic enzyme replacement market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pancreatic enzyme replacement market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pancreatic enzyme replacement market by increasing costs for imported enzyme formulations, tablets, capsules, and powder delivery systems. Hospital pharmacies, retail pharmacies, and online pharmacies in north america, europe, and asia-pacific face the most pressure due to reliance on imported synthetic and recombinant enzymes. While tariffs raise costs, they also incentivize local production, encourage innovation in cost-effective enzyme formulations, and strengthen domestic supply chains.

The pancreatic enzyme replacement market research report is one of a series of new reports that provides pancreatic enzyme replacement market statistics, including pancreatic enzyme replacement industry global market size, regional shares, competitors with a pancreatic enzyme replacement market share, detailed pancreatic enzyme replacement market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic enzyme replacement industry. This pancreatic enzyme replacement market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pancreatic enzyme replacement therapy (PERT) is used to treat patients with insufficient pancreatic enzyme production. It provides synthetic enzymes - amylase, lipase, and protease - that aid in the digestion of carbohydrates, fats, and proteins. These enzymes act in the small intestine to break down macronutrients into absorbable molecules, improving nutrient absorption and reducing symptoms such as malnutrition, weight loss, and digestive discomfort in individuals with pancreatic insufficiency.

The main product types of pancreatic enzyme replacement therapy include tablets, capsules, powders, and other formulations. Tablets are oral medications that deliver essential enzymes to support digestion in patients with pancreatic insufficiency. The enzymes are sourced from porcine, microbial, or recombinant origins and are used in conditions such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and other disorders affecting pancreatic function. These products are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, serving end users including hospitals, clinics, and home healthcare settings.

The pancreatic enzyme replacement market consists of revenues earned by entities by providing services such as enzyme supplementation, personalized treatment plans, patient education and support, and ongoing monitoring and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic enzyme replacement market also includes sales of creon, zenpep, pancreaze, ultresa, and pertzye. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.